Sienna Biopharmaceuticals, Inc., a Westlake Village, CA-based clinical stage company focused on medical dermatology and aesthetics, secured an additional $12m in the second closing of its Series A financing.
This tranche was led by existing investors Arch Venture Partners and Partner Fund Management and included new investor Two River. Additional investors in the initial Series A included Altitude Life Science Ventures and Venvest Capital, as well as direct investment by aesthetics and medical dermatology industry professionals.
The company, which has raised approximately $46m in total funding, intends to use the funds for pharmaceutical research and advancement of its business development efforts.
Led by Frederick C. Beddingfield III, MD, PhD, President and CEO, Sienna Biopharmaceuticals focuses on the discovery, clinical development and commercialization of innovative medical dermatology and aesthetics products based on scientific discoveries. Its lead proprietary technology, Silver Plasmonic Therapy (SPT), has promising applications for acne and permanent hair removal while the evaluation of additional potential indications is underway.